{"id":919582,"date":"2025-12-15T08:16:23","date_gmt":"2025-12-15T13:16:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/"},"modified":"2025-12-15T08:16:23","modified_gmt":"2025-12-15T13:16:23","slug":"silence-therapeutics-announces-leadership-changes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/","title":{"rendered":"Silence Therapeutics Announces Leadership Changes"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Silence Therapeutics Announces Leadership Changes<\/b><\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company\u2019s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025.\n<\/p>\n<p>\nIain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company\u2019s Board of Directors. An additional appointment of an US-based Board member is anticipated in due course.\n<\/p>\n<p>\nIain Ross, Chairman of Silence, said: &#8220;We thank Craig for his many contributions to Silence and wish him well for the future. The Company is in robust health both financially and operationally, and we look forward to further commercial and scientific advancements with our pipeline.\u201d\n<\/p>\n<p><b>About Silence Therapeutics<\/b><\/p>\n<p>\nSilence Therapeutics is a global clinical-stage biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD\u2122 platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https:\/\/www.silence-therapeutics.com\/.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpositioned,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company\u2019s business strategy and plans, including the Company\u2019s anticipated financial and operational health; anticipated changes to the Company\u2019s Board of Directors and the Company\u2019s ability to develop further commercial and scientific advancements with its pipeline. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the Company\u2019s history of net operating losses; the Company\u2019s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the Company\u2019s product candidates; the Company\u2019s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the Company\u2019s product candidates; the Company\u2019s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the Company\u2019s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled \u201cRisk Factors\u201d contained in the Company\u2019s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the Company\u2019s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251215323930\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251215323930\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries:<\/b><\/p>\n<p><b>Silence Therapeutics plc<br \/>\n<\/b><br \/>Gem Hopkins, VP, IR and Corporate Communications<br \/>\n<br \/>Tel: +1 (646) 637-3208<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@silence-therapeutics.com\">ir@silence-therapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Other Health Health Genetics Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Silence Therapeutics Announces Leadership Changes LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company\u2019s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company\u2019s Board of Directors. An additional appointment of an US-based Board member is anticipated in due course. Iain Ross, Chairman of Silence, said: &#8220;We thank Craig &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silence Therapeutics Announces Leadership Changes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics Announces Leadership Changes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics Announces Leadership Changes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silence Therapeutics Announces Leadership Changes LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company\u2019s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company\u2019s Board of Directors. An additional appointment of an US-based Board member is anticipated in due course. Iain Ross, Chairman of Silence, said: &#8220;We thank Craig &hellip; Continue reading &quot;Silence Therapeutics Announces Leadership Changes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T13:16:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silence Therapeutics Announces Leadership Changes\",\"datePublished\":\"2025-12-15T13:16:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/\",\"name\":\"Silence Therapeutics Announces Leadership Changes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-12-15T13:16:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-announces-leadership-changes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics Announces Leadership Changes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics Announces Leadership Changes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics Announces Leadership Changes - Market Newsdesk","og_description":"Silence Therapeutics Announces Leadership Changes LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company\u2019s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company\u2019s Board of Directors. An additional appointment of an US-based Board member is anticipated in due course. Iain Ross, Chairman of Silence, said: &#8220;We thank Craig &hellip; Continue reading \"Silence Therapeutics Announces Leadership Changes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T13:16:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silence Therapeutics Announces Leadership Changes","datePublished":"2025-12-15T13:16:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/","name":"Silence Therapeutics Announces Leadership Changes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-12-15T13:16:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251215323930r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-announces-leadership-changes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics Announces Leadership Changes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}